KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zimmer Biomet Holdings (ZBH) Cash & Equivalents (2016 - 2025)

Zimmer Biomet Holdings (ZBH) has 17 years of Cash & Equivalents data on record, last reported at $591.9 million in Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 12.64% year-over-year to $591.9 million; the TTM value through Dec 2025 reached $591.9 million, up 12.64%, while the annual FY2025 figure was $591.9 million, 12.64% up from the prior year.
  • Cash & Equivalents reached $591.9 million in Q4 2025 per ZBH's latest filing, down from $1.3 billion in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $1.4 billion in Q1 2025 and bottomed at $292.1 million in Q3 2023.
  • Average Cash & Equivalents over 5 years is $595.0 million, with a median of $480.6 million recorded in 2022.
  • Peak YoY movement for Cash & Equivalents: tumbled 70.24% in 2021, then soared 252.29% in 2025.
  • A 5-year view of Cash & Equivalents shows it stood at $378.1 million in 2021, then dropped by 0.63% to $375.7 million in 2022, then rose by 10.67% to $415.8 million in 2023, then rose by 26.38% to $525.5 million in 2024, then rose by 12.64% to $591.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $591.9 million in Q4 2025, $1.3 billion in Q3 2025, and $556.9 million in Q2 2025.